Healthcare Realty Trust Incorporated
HR
$19.30
-0.31%
Healthcare Realty Trust Incorporated is a real estate investment trust (REIT) focused on owning, leasing, and managing outpatient medical facilities and other healthcare properties across the United States. As a specialized healthcare REIT, it distinguishes itself by concentrating on properties integral to hospital operations, such as medical office buildings and outpatient centers, positioning it as a key player in the healthcare real estate niche. The current investor narrative centers on the company's ongoing portfolio optimization and balance sheet deleveraging, as evidenced by significant debt repayments and asset sales, while the stock has shown strong price appreciation over the past year, reflecting improving market sentiment and a potential turnaround in operational performance.…
HR
Healthcare Realty Trust Incorporated
$19.30
Investment Opinion: Should I buy HR Today?
Based on the data, HR is rated a 'Hold'. The stock has strong momentum and a discounted valuation, but the declining revenue and lack of profitability warrant caution. The average analyst target of $21.33 is close to the current price, implying limited upside, and the consensus is neutral. The thesis is that the company is in a turnaround phase, but it needs to demonstrate revenue stabilization and improved profitability to justify a higher valuation.
Sign up to view all
HR 12-Month Price Forecast
The AI model assesses HR as neutral, reflecting a balance between the discounted valuation and the ongoing operational challenges. The stock's strong price momentum and improving earnings trajectory are positive, but the declining revenue and high leverage temper enthusiasm. The model would upgrade to bullish if revenue growth turns positive and net income becomes consistently positive, or if the stock pulls back to a more attractive valuation. Conversely, a downgrade to bearish would occur if revenue decline accelerates or the company faces liquidity issues.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Healthcare Realty Trust Incorporated's 12-month outlook, with a consensus price target around $21.50 and implied upside of +11.4% versus the current price.
Average Target
$21.50
0 analysts
Implied Upside
+11.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$18 - $24
Analyst target range
The target price range spans from $18.00 (low) to $24.00 (high), indicating a wide dispersion of expectations. The low target of $18.00 implies a potential downside of -14.3%, while the high target of $24.00 suggests an upside of +14.2%. This wide range reflects significant uncertainty about the company's future performance, likely due to the ongoing portfolio transformation and the impact of interest rates on REIT valuations. Recent institutional ratings have been predominantly neutral, with firms like JP Morgan, UBS, and Wells Fargo maintaining 'Neutral' or 'Equal Weight' stances, while a few like Cantor Fitzgerald and Scotiabank are more positive. The lack of recent upgrades or downgrades suggests that analysts are in a wait-and-see mode, awaiting clearer signs of operational stabilization.
Bulls vs Bears: HR Investment Factors
Healthcare Realty Trust presents a mixed picture: strong price momentum and a discounted valuation are countered by declining revenue and persistent unprofitability. The bull case rests on successful portfolio transformation and potential earnings recovery, while the bear case highlights top-line shrinkage and high leverage. Currently, the evidence slightly favors the bulls due to the significant valuation discount and improving earnings trend, but the key tension is whether revenue can stabilize and grow after asset sales. If revenue continues to decline, the stock could face a re-rating downward; if it stabilizes and profitability improves, the stock has substantial upside potential.
Bullish
- Strong price momentum and relative strength: HR is up 36.78% over the past year and 25.13% over six months, significantly outperforming the S&P 500 (18.19% and 7.96% respectively). Relative strength of 18.59 over one year indicates robust market confidence in the turnaround story.
- Portfolio optimization and deleveraging: The company is actively selling non-core assets and repaying debt, as evidenced by a debt-to-equity ratio of 0.90 and a current ratio of 1.75. This strategic focus on higher-quality properties should improve long-term cash flow stability and reduce financial risk.
- Valuation at a significant discount to history: The price-to-sales ratio of 5.02x is far below the historical average of around 20x, suggesting the market is pricing in past struggles. If the company returns to profitability and revenue stabilizes, there is potential for multiple expansion and share price appreciation.
- Positive earnings trajectory in recent quarters: EPS improved from -$0.45 in Q2 2025 to -$0.0021 in Q1 2026, and Q4 2025 posted positive EPS of $0.0398. This trend indicates that cost-cutting and portfolio changes are beginning to yield results, potentially leading to sustained profitability.
Bearish
- Declining revenue trend: Revenue has fallen from $316.32 million in Q2 2024 to $278.99 million in Q1 2026, a 6.69% year-over-year decline in the latest quarter. This persistent top-line contraction raises concerns about the company's ability to grow, even as it optimizes its portfolio.
- Negative profitability and thin margins: Trailing EPS is -$0.04, and the net margin is -20.84%. While operating margin improved to 8.04%, the company still struggles to generate consistent profits, and the gross margin is negative (-33.58%) due to high depreciation and amortization costs.
- High leverage and interest burden: With a debt-to-equity ratio of 0.90 and interest expenses of $42.2 million in Q1 2026, the company is sensitive to interest rate fluctuations. Higher rates could increase borrowing costs and pressure cash flows, especially in a rate-hiking environment.
- Analyst consensus is neutral: The recommendation is 'hold' with a mean score of 2.54, and major firms like JP Morgan, UBS, and Wells Fargo maintain neutral stances. This lack of bullish conviction suggests that analysts see limited near-term upside and are waiting for clearer signs of stabilization.
HR Technical Analysis
Healthcare Realty Trust's stock is in a clear uptrend, with a 1-year price change of +36.78% and a 6-month change of +25.13%. The current price of $21.01 sits at 95.3% of its 52-week range (low $15.30, high $22.04), indicating the stock is trading near its highs, which typically signals strong momentum but also potential overextension. This positioning suggests that investors are optimistic about the company's recovery, though the proximity to the 52-week high may limit short-term upside without a breakout.
Beta
0.82
0.82x market volatility
Max Drawdown
-13.4%
Largest decline past year
52-Week Range
$16-$22
Price range past year
Annual Return
+11.7%
Cumulative gain past year
| Period | HR Return | S&P 500 |
|---|---|---|
| 1m | -6.0% | +1.0% |
| 3m | -1.4% | +1.1% |
| 6m | +4.9% | +13.8% |
| 1y | +11.7% | +19.5% |
| ytd | +13.9% | +12.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HR Fundamental Analysis
Revenue has been declining, with the most recent quarter (Q1 2026) showing revenue of $278.99 million, a 6.69% year-over-year decrease. This follows a trend of shrinking revenue from $316.32 million in Q2 2024 to $278.99 million in Q1 2026, indicating a deceleration in top-line growth. The decline is partly due to asset sales and portfolio rationalization, as the company focuses on higher-quality properties, but it also reflects a challenging operating environment for healthcare REITs.
Quarterly Revenue
$278990000.0B
2026-03
Revenue YoY Growth
-6.7%
YoY Comparison
Gross Margin
64.1%
Latest Quarter
Free Cash Flow
$140005000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HR Overvalued?
Given that Healthcare Realty Trust has negative trailing earnings (EPS of -$0.04), the price-to-sales (PS) ratio is the most appropriate valuation metric, as it allows for comparison regardless of profitability. The current PS ratio is 5.02x, which is significantly lower than the historical average of around 20x, suggesting the stock is trading at a substantial discount to its own past valuation. This could indicate that the market is pricing in the company's recent struggles, but also that there is potential for re-rating if the company returns to profitability.
PE
-23.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 25x~184x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. The company has a high debt-to-equity ratio of 0.90, and interest expenses of $42.2 million in Q1 2026 consume a large portion of operating income. Cash flow generation is weak, with free cash flow of $140 million TTM, but negative net income and a net margin of -20.84% indicate that the company is not yet self-sustaining. Revenue concentration in healthcare properties exposes it to sector-specific downturns, and the declining revenue trend (down 6.69% YoY) suggests that asset sales are shrinking the top line faster than new investments are adding to it.
FAQ
The key risks are: 1) Financial risk: high debt-to-equity of 0.90 and negative net income, which could lead to liquidity issues if interest rates rise. 2) Operational risk: declining revenue (down 6.69% YoY) and negative gross margins, indicating that the portfolio is not generating enough income. 3) Market risk: the stock is trading near its 52-week high, and a pullback could be sharp if sentiment turns. 4) Sector risk: healthcare REITs are sensitive to changes in healthcare policy and tenant demand. The most severe risk is a continued revenue decline that forces further asset sales at depressed prices, eroding shareholder value.
The 12-month forecast is mixed. The bull case (25% probability) sees the stock reaching $22-$24 if revenue stabilizes and profitability improves. The base case (50% probability) expects the stock to trade around $20-$22, in line with the average analyst target of $21.33. The bear case (25% probability) could see the stock fall to $15.30-$18 if revenue decline accelerates and interest rates rise. The most likely scenario is the base case, assuming the company continues its gradual improvement but does not achieve a rapid turnaround.
HR appears undervalued relative to its own history, with a PS ratio of 5.02x versus a historical average of around 20x. This suggests the market is pricing in significant pessimism about the company's future. However, the negative earnings and declining revenue justify a lower multiple. The PEG ratio of 0.39 indicates that the stock is cheap relative to expected growth, but that growth is uncertain. Overall, the valuation is reasonable if the company can stabilize revenue and return to profitability, but it is not a clear bargain given the operational risks.
HR is a hold for most investors. The stock has strong momentum (up 36.78% over the past year) and trades at a PS ratio of 5.02x, well below its historical average of 20x, suggesting potential upside if the turnaround succeeds. However, revenue is declining (down 6.69% YoY) and the company is not yet profitable, with a trailing EPS of -$0.04. The average analyst target of $21.33 offers only 1.5% upside, and the low target implies a -14.3% downside. It could be a good buy for investors who believe in the portfolio optimization story and are willing to wait for revenue stabilization, but it is not a low-risk investment.
HR is more suitable for long-term investment, given its turnaround nature and the time needed for portfolio optimization to bear fruit. The stock has a beta that is not provided, but its 36.78% one-year gain suggests significant volatility, making it risky for short-term traders. The dividend yield of 6.53% provides some income, but the payout ratio is negative, indicating the dividend may be at risk. For long-term investors, a holding period of at least 3-5 years is recommended to allow the company to stabilize revenue and achieve sustainable profitability. Short-term traders might find opportunities in the momentum, but the limited upside to analyst targets and high volatility make it a less attractive short-term play.